175 related articles for article (PubMed ID: 19656325)
1. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.
Harms JH; Lautenschlager S; Minder CE; Minder EI
Photochem Photobiol; 2009; 85(6):1434-9. PubMed ID: 19656325
[TBL] [Abstract][Full Text] [Related]
2. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.
Minder EI
Expert Opin Investig Drugs; 2010 Dec; 19(12):1591-602. PubMed ID: 21073357
[TBL] [Abstract][Full Text] [Related]
3. Afamelanotide: A Review in Erythropoietic Protoporphyria.
Kim ES; Garnock-Jones KP
Am J Clin Dermatol; 2016 Apr; 17(2):179-85. PubMed ID: 26979527
[TBL] [Abstract][Full Text] [Related]
4. A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.
Spichty R; Balimann M; Barman J; Minder EI
J Pharm Biomed Anal; 2013 Mar; 75():192-8. PubMed ID: 23277150
[TBL] [Abstract][Full Text] [Related]
5. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.
Wensink D; Wagenmakers MAEM; Langendonk JG
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):151-160. PubMed ID: 33507118
[No Abstract] [Full Text] [Related]
6. A review and update on melanocyte stimulating hormone therapy: afamelanotide.
Fabrikant J; Touloei K; Brown SM
J Drugs Dermatol; 2013 Jul; 12(7):775-9. PubMed ID: 23884489
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.
Minder EI; Barman-Aksoezen J; Schneider-Yin X
Clin Pharmacokinet; 2017 Aug; 56(8):815-823. PubMed ID: 28063031
[TBL] [Abstract][Full Text] [Related]
8. Afamelanotide for Erythropoietic Protoporphyria.
Langendonk JG; Balwani M; Anderson KE; Bonkovsky HL; Anstey AV; Bissell DM; Bloomer J; Edwards C; Neumann NJ; Parker C; Phillips JD; Lim HW; Hamzavi I; Deybach JC; Kauppinen R; Rhodes LE; Frank J; Murphy GM; Karstens FPJ; Sijbrands EJG; de Rooij FWM; Lebwohl M; Naik H; Goding CR; Wilson JHP; Desnick RJ
N Engl J Med; 2015 Jul; 373(1):48-59. PubMed ID: 26132941
[TBL] [Abstract][Full Text] [Related]
9. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria.
Harms J; Lautenschlager S; Minder CE; Minder EI
N Engl J Med; 2009 Jan; 360(3):306-7. PubMed ID: 19144952
[No Abstract] [Full Text] [Related]
10. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.
Minder AE; Barman-Aksoezen J; Schmid M; Minder EI; Zulewski H; Minder CE; Schneider-Yin X
Ther Adv Rare Dis; 2021; 2():26330040211065453. PubMed ID: 37181106
[TBL] [Abstract][Full Text] [Related]
11. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.
Minder EI; Schneider-Yin X
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):43-53. PubMed ID: 25470471
[TBL] [Abstract][Full Text] [Related]
12. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.
Resnik SR; Targett D; Resnik BI
J Drugs Dermatol; 2023 Sep; 22(9):941-949. PubMed ID: 37683058
[TBL] [Abstract][Full Text] [Related]
13. Alpha-melanocyte stimulating hormone analogues: the perils and the promise.
Mazza JM; Zippin JH
J Drugs Dermatol; 2009 Aug; 8(8):772-6. PubMed ID: 19663117
[No Abstract] [Full Text] [Related]
14. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.
Dorr RT; Ertl G; Levine N; Brooks C; Bangert JL; Powell MB; Humphrey S; Alberts DS
Arch Dermatol; 2004 Jul; 140(7):827-35. PubMed ID: 15262693
[TBL] [Abstract][Full Text] [Related]
15. Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.
Barman-Aksözen J; Nydegger M; Schneider-Yin X; Minder AE
Orphanet J Rare Dis; 2020 Aug; 15(1):213. PubMed ID: 32811524
[TBL] [Abstract][Full Text] [Related]
16. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.
Biolcati G; Marchesini E; Sorge F; Barbieri L; Schneider-Yin X; Minder EI
Br J Dermatol; 2015 Jun; 172(6):1601-1612. PubMed ID: 25494545
[TBL] [Abstract][Full Text] [Related]
17. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.
Wensink D; Wagenmakers MAEM; Barman-Aksözen J; Friesema ECH; Wilson JHP; van Rosmalen J; Langendonk JG
JAMA Dermatol; 2020 May; 156(5):570-575. PubMed ID: 32186677
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.
Lengweiler S; Kreim S; Barman-Aksözen J; Maurer M; Minder EI
Skin Pharmacol Physiol; 2015; 28(2):103-13. PubMed ID: 25402764
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris.
Böhm M; Ehrchen J; Luger TA
J Eur Acad Dermatol Venereol; 2014 Jan; 28(1):108-11. PubMed ID: 22845050
[TBL] [Abstract][Full Text] [Related]
20. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH.
Haylett AK; Nie Z; Brownrigg M; Taylor R; Rhodes LE
Br J Dermatol; 2011 Feb; 164(2):407-14. PubMed ID: 20969564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
